ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0537

The Clinical, Oral Small Molecule IRAK4 Inhibitor, GS-5718, Improves Survival and Reduces Disease Pathologies by Modulating Multiple Inflammatory Endpoints in the Murine NZB/W Model of Spontaneous Lupus

Adam Yadon1, Vanessa Gorney2, Angie Hammond3, Ethan Grant2 and Astrid Clarke3, 1Gilead Sciences, Inc., Seattle, WA, 2Gilead Sciences, Inc, Foster City, CA, 3Gilead Sciences, Inc, Seattle, WA

Meeting: ACR Convergence 2021

Keywords: Autoinflammatory diseases, lupus-like disease, Mouse Models, Lupus, Protein Kinase, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: SLE – Animal Models Poster (0534–0540)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Lupus is a heterogenous autoimmune disease characterized by loss of immune tolerance, production of nucleic acid:autoantibody immune complexes, immune cell hyperactivation, and increased proinflammatory cytokine and interferon production. Interleukin receptor associated kinase 4 (IRAK4) is a serine/threonine kinase that modulates proinflammatory cytokine and type I interferon production downstream of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs) in immune cells. It is well established that TLR signaling (predominately TLR7 and TLR9) plays a key role in the pathogenesis of lupus1 and thus inhibition of IRAK4 represents a promising target for the therapeutic treatment of lupus.

The murine NZB/W model recapitulates many lupus-like disease pathologies including proteinuria, hyperactive B and T cells, high titers of autoantibodies, and splenic and kidney abnormalities2,3. Current standard of care treatments, including methotrexate, cyclophosphamide, mycophenolate mofetil, and blockers of B-cell activating factor (BAFF) have demonstrated efficacy (e.g. improved survival and/or clinical pathologies) in this model2,3. Demonstrating beneficial effects of IRAK4 inhibition in this model would support clinical evaluation in lupus.

Methods: In this study we investigated the efficacy of GS-5718, a highly selective, competitive inhibitor of IRAK4, to improve survival and attenuate disease pathology in the murine NZB/W model of spontaneous lupus.

Results: GS-5718 treated animals displayed improved in-life disease outcomes, histological measures, and pharmacodynamically reduced multiple inflammatory endpoints. Administration of GS-5718 showed statistically significant improvements in survival and reduced proteinuria, splenomegaly, and serum cholesterol levels compared to control animals. Kidney histology revealed GS-5718 treatment decreased swelling, crescent formation and periodic acid-Schiff (PAS) staining in glomeruli, protein casts in the cortex, and perivascular infiltration. These improvements in disease pathologies were accompanied by statistically significant reductions in peripheral cytokine production, kidney cytokine and interferon gene expression, and splenic immune cell infiltration.

Conclusion: GS-5718 treatment showed statistically significant improvements in survival and disease progression in a murine NZB/W spontaneous lupus model accompanied by improvements in pharmacodynamic inflammatory endpoints. These results suggest a pathological role for IRAK4 signaling in a pre-clinical mouse lupus model and supports further evaluation of GS-5718 for therapeutic intervention in lupus patients.

References
1 Devarapu, S. K. & Anders, H. J. Toll-like receptors in lupus nephritis. J Biomed Sci 25, 35 (2018).
2 Perry, D., Sang, A., Yin, Y., Zheng, Y. Y. & Morel, L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol 2011, 271694 (2011).
3 Celhar, T. & Fairhurst, A. M. Modelling clinical systemic lupus erythematosus: similarities, differences and success stories. Rheumatology (Oxford) 56, i88-i99 (2017).

(A) Total proteinuria score (area under curve, AUC, weeks 28 to 38). (B) Composite kidney score (glomerulus, crescent, protein cast, interstitial inflammation, and vasculitis score). Cyclo., Cyclophosphamide; %, Percent change from untreated disease; *, p-value < 0.05 Kruskal-Wallis (Dunn’s post-hoc) vs. untreated disease

(A-C) Z-scores of gene expression changes (fold-change relative to untreated disease) for proinflammatory cytokines (A), type I IFNs (B), and type II IFNs (C) genes. Cyclo., Cyclophosphamide; *, p-value < 0.05 Kruskal-Wallis (Dunn’s post-hoc) vs. untreated disease


Disclosures: A. Yadon, Gilead Sciences, Inc., 3; V. Gorney, Gilead Sciences, Inc., 3; A. Hammond, Gilead Sciences, Inc., 3; E. Grant, Gilead Sciences, Inc., 3; A. Clarke, Gilead Sciences, Inc., 3.

To cite this abstract in AMA style:

Yadon A, Gorney V, Hammond A, Grant E, Clarke A. The Clinical, Oral Small Molecule IRAK4 Inhibitor, GS-5718, Improves Survival and Reduces Disease Pathologies by Modulating Multiple Inflammatory Endpoints in the Murine NZB/W Model of Spontaneous Lupus [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-clinical-oral-small-molecule-irak4-inhibitor-gs-5718-improves-survival-and-reduces-disease-pathologies-by-modulating-multiple-inflammatory-endpoints-in-the-murine-nzb-w-model-of-spontaneous-lup/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-clinical-oral-small-molecule-irak4-inhibitor-gs-5718-improves-survival-and-reduces-disease-pathologies-by-modulating-multiple-inflammatory-endpoints-in-the-murine-nzb-w-model-of-spontaneous-lup/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology